Şencan, İrfanŞahin, İdrisÖzçetin, Adnan2021-06-232021-06-2320041060-0280https://doi.org/10.1345/aph.1D205https://hdl.handle.net/20.500.12491/5629Venlafaxine is metabolized in the liver by the isoenzyme CYP2D6. Venlafaxine-associated adverse effects have been reported, such as gastrointestinal and autonomic effects. With the usage of high dosages of venlafaxine,1 adverse effects such as toxic hepatitis have been reported,2,3 but toxic hepatitis has not been reported at low doses of venlafaxine such as 37.5 mg/day. We report a case of probable toxic hepatitis associated with a low dose of venlafaxine in a patient with a history of chronic hepatitis.eninfo:eu-repo/semantics/closedAccessChronic HepatitisLiver ToxicityVenlafaxineLetter10.1345/aph.1D205382352353147427792-s2.0-1642580645Q1WOS:000188188100030Q3